You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 43 No. 10, October 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Dopamine Metabolism in the Cerebrospinal Fluid of Drug-Free Schizophrenic Patients With and Without Cortical Atrophy

Daniel P. van Kammen, MD, PhD; Welmoet Bok van Kammen, PhD; Lee S. Mann, MD; Timo Seppala, MD, PhD; Markku Linnoila, MD, PhD

Arch Gen Psychiatry. 1986;43(10):978-983.


Abstract

• Cortical atrophy measured with computed tomography was observed in ten of 53 schizophrenic patients. Levels of homovanillic acid, dihydroxyphenyl acetic acid (DOPAC), conjugated DOPAC, and dopamine sulfate (DASO4) were measured in the cerebrospinal fluid of these patients during a drug-free evaluation. Patients with cortical atrophy had lower cerebrospinal fluid levels of homovanillic acid, DOPAC, and conjugated DOPAC but higher DASO4 levels. Combined measures of dopamine utilization were significantly lower in patients with cortical atrophy. We did not find significant clinical or demographic differences between the patients with and without cortical atrophy. Patients without brain atrophy who had dopamine utilization above the mean showed more psychotic symptoms and shorter duration of illness, while those with dopamine below the mean had more negative symptoms. We propose that both state- and trait-dependent variables affect dopamine turnover.



Author Affiliations

From the Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh (Drs D. van Kammen and W. van Kammen); Psychiatry Service, Veterans Administration Medical Center, Pittsburgh (Dr D. van Kammen); Department of Psychiatry, Fairfax Hospital, Falls Church, Va (Dr Mann); Department of Pharmacology, University of Helsinki (Dr Seppala); and Laboratory of Clinical Studies, Division of Intramural Clinical and Biological Research, National Institute of Alcohol Abuse and Alcoholism, Bethesda, Md (Dr Linnoila).


Footnotes

Accepted for publication May 23, 1986.

Reprint requests to Psychiatry Service, Veterans Administration Medical Center, Highland Drive, Pittsburgh, PA 15206 (Dr D. van Kammen).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Anterior Cingulate Neurons Represent Errors and Preparatory Attention within the Same Behavioral Sequence
Totah et al.
J. Neurosci. 2009;29:6418-6426.
ABSTRACT | FULL TEXT  

Executive Control Function: A Review of Its Promise and Challenges for Clinical Research. A Report From the Committee on Research of the American Neuropsychiatric Association
Royall et al.
J. Neuropsychiatry Clin. Neurosi. 2002;14:377-405.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid and Plasma Monoamine Metabolites and Their Relation to Psychosis: Implications for Regional Brain Dysfunction in Schizophrenia
Pickar et al.
Arch Gen Psychiatry 1990;47:641-648.
ABSTRACT  

Norepinephrine in Acute Exacerbations of Chronic Schizophrenia: Negative Symptoms Revisited
van Kammen et al.
Arch Gen Psychiatry 1990;47:161-168.
ABSTRACT  

Cholinergic Hyperactivity and Negative Schizophrenic Symptoms: A Model of Cholinergic/Dopaminergic Interactions in Schizophrenia
Tandon and Greden
Arch Gen Psychiatry 1989;46:745-753.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.